Drug Trial Radar · NCT04856371
Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Apr 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
228
Planned (sponsor's estimate)
Start
Apr 2021
Primary completion
Mar 2022
Study completion Dec 2022
Sponsor
- Lead sponsor
- Haihe Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, phase Ib study designed to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of CYH33 administered orally in combination with standard-of-care ET ± CDK4/6 inhibitor therapies for the treatment of locally advanced, recurrent or metastatic hormone-receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Patients will be enrolled in two stages, including dose exploration phase (Stage 1) and dose expansion phase (Stage 2) of each cohort.
Conditions
- Advanced Breast Cancer
Interventions
CYH33Drug
Participants will receive oral CYH33 once daily on Days 1-28 of each 28-day cycle.
FulvestrantDrug
Participants will receive fulvestrant 500 mg, administered intramuscularly on Days 1, 15 on Cycle 1 (28-day cycle) and Day 1 at each 28-day cycle thereafter.
LetrozoleDrug
Participants will receive oral letrozole once daily continuous on Day 1-28 of each cycle.
PalbociclibDrug
Participants will receive palbociclib once daily continuous on Day 1-21 of each 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicities (DLT)Time frame: 28 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.